LBPH Stock Price, Longboard Pharmaceuticals, . Quote, Chart

Market Summary

USD20.53+0.02

Delayedas of 17 May 2024, 12:01 pm

0.10%

LBPH Stock Price

View Fullscreen

LBPH RSI Chart

LBPH Valuation

Market Cap

797.4M

Price/Earnings (Trailing)

-13.76

Price/Free Cashflow

-15.06

LBPH Price/Earnings (Trailing)

LBPH Profitability

Return on Equity

-18.47%

Return on Assets

-17.69%

Free Cashflow Yield

-6.64%

LBPH Fundamentals

LBPH Earnings

Earnings (TTM)

-58.0M

Earnings Growth (Yr)

-30.81%

Earnings Growth (Qtr)

0.31%

Breaking Down LBPH Revenue

52 Week Range

4.3420.75

(Low)(High)

Last 7 days

-6.6%

Last 30 days

12.6%

Last 90 days

-3.4%

Trailing 12 Months

118.5%

How does LBPH drawdown profile look like?

LBPH Financial Health

Current Ratio

31.43

LBPH Investor Care

Shares Dilution (1Y)

69.27%

Diluted EPS (TTM)

-2.25

Tracking the Latest Insider Buys and Sells of Longboard Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 08, 2024	kaye randall	acquired	-	-	17,920	cmo
Feb 08, 2024	roberts brandi	acquired	-	-	15,090	cfo
Jan 25, 2024	arena pharmaceuticals inc	sold	-96,479,600	24.25	-3,978,540	-
Mar 16, 2021	arena pharmaceuticals inc	acquired	-	-	138,000	-

Which funds bought or sold LBPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-92.33	-7,243	2,743	-%
May 15, 2024	Voya Investment Management LLC	new	-	768,442	768,442	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	sold off	-100	-1,395,770	-	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	reduced	-56.13	424,613	1,167,540	0.08%
May 15, 2024	Cormorant Asset Management, LP	added	42.5	58,238,400	72,427,800	3.18%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	2,308,720	2,308,720	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	11,513,600	11,513,600	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	12,236,400	12,236,400	0.02%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	new	-	71,045,000	71,045,000	0.91%
May 15, 2024	Laurion Capital Management LP	added	212	1,348,670	1,480,790	0.01%

Are Funds Buying or Selling LBPH?

Are funds buying LBPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LBPH

No. of Funds

Unveiling Longboard Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	7.6%	1,626,982	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	3.8%	825,000	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	4.79%	1,027,679	SC 13G/A
Feb 13, 2024	prosight management, lp	0.0%	0	SC 13G/A
Feb 13, 2024	hbm healthcare investments (cayman) ltd.	0%	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 30, 2024	farallon capital partners, l.p.	5.5%	1,205,990	SC 13G/A
Jan 29, 2024	pfizer inc	0.00%	0	SC 13D/A
Jan 26, 2024	integrated core strategies (us) llc	0.0%	6,603	SC 13G/A

Recent SEC filings of Longboard Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 12, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Mar 28, 2024	PRE 14A	PRE 14A
Mar 26, 2024	8-K	Current Report
Mar 12, 2024	S-3ASR	S-3ASR
Mar 12, 2024	10-K	Annual Report

Peers (Alternatives to Longboard Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Longboard Pharmaceuticals, Inc. News

Latest updates

Longboard Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	546.3%	328	51.00	59.00	66.00	80.00	71.00	81.00	91.00	101	109	116	121	124	56.00
Current Assets	544.0%	323	50.00	58.00	66.00	79.00	70.00	80.00	90.00	100	108	115	121	124	55.00
Cash Equivalents	281.3%	55.00	14.00	24.00	20.00	25.00	11.00	19.00	28.00	35.00	66.00	75.00	91.00	121	55.00
Net PPE	-25.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Current Liabilities	5.3%	10.00	10.00	7.00	8.00	7.00	9.00	8.00	8.00	7.00	5.00	4.00	3.00	4.00	3.00
Shareholder's Equity	666.6%	314	41.00	52.00	58.00	72.00	61.00	72.00	83.00	94.00	103	112	117	120	-
Retained Earnings	-10.7%	-155	-140	-125	-112	-97.60	-86.10	-74.80	-63.20	-51.80	-42.20	-33.42	-27.10	-20.10	-14.40
Additional Paid-In Capital	158.7%	470	182	178	171	170	148	148	147	146	146	145	145	140	12.00
Shares Outstanding	52.1%	34.00	22.00	21.00	21.00	21.00	14.00	17.00	17.00	17.00	13.00	17.00	17.00	-	-
Float	-	-	-	-	148	-	-	-	52.00	-	-	-	117,500	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-37.6%	-15,177	-11,028	-13,289	-13,454	-13,097	-9,671	-9,853	-8,514	-10,025	-5,675	-6,134	-5,150	-7,746	-1,459	-1,041	-903	-39.00
Share Based Compensation	103.4%	1,749	860	856	841	697	592	795	699	571	584	538	512	333	7,360	498	555	95.00
Cashflow From Investing	-14693.0%	-230,919	-1,561	11,749	7,962	6,083	2,145	882	1,193	-21,284	-	-	-	-	-	-	-	-
Cashflow From Financing	9415.1%	286,404	3,010	5,946	-125	21,360	-444	-	-	-	-	-2.00	3,172	73,281	-	-	-	39.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LBPH Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 13,170	$ 8,530
General and administrative	4,940	3,432
Total operating expenses	18,110	11,962
Loss from operations	(18,110)	(11,962)
Interest income, net	3,133	516
Other expense	(9)	(10)
Net loss	$ (14,986)	$ (11,456)
Net loss per share, basic	$ (0.42)	$ (0.56)
Net loss per share, diluted	$ (0.42)	$ (0.56)
Weighted-average shares outstanding, basic	35,321,794	20,409,794
Weighted-average shares outstanding, diluted	35,321,794	20,409,794
Comprehensive loss:
Net loss	$ (14,986)	$ (11,456)
Unrealized gain (loss) on short-term investments	(288)	271
Comprehensive loss	$ (15,274)	$ (11,185)

LBPH Balance Sheet

2024-03-31

Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 54,395	$ 14,331
Short-term Investments	266,648	34,167
Prepaid expenses and other current assets	2,398	1,723
Total current assets	323,441	50,221
Right-of-use assets	3,977	472
Property and equipment	3	4
Other long-term assets	244	0
Total assets	327,665	50,697
Current liabilities:
Accounts payable	1,045	1,001
Accrued research and development expenses	7,304	4,556
Accrued compensation and related expenses	1,054	3,374
Accrued other expenses	572	368
Right-of-use liabilities, current portion	315	475
Total current liabilities	10,290	9,774
Right-of-use liabilities, net of current portion	3,667	0
Commitments and contingencies (see Note 9)
Stockholders' equity:
Preferred Stock, Value, Issued	0	0
Common Stock, Value, Issued	3	2
Additional paid-in-capital	469,621	181,563
Accumulated other comprehensive loss	(366)	(78)
Accumulated deficit	(155,550)	(140,564)
Total stockholders' equity	313,708	40,923
Total liabilities and stockholders' equity	327,665	50,697
Non-Voting Common Stock [Member]
Stockholders' equity:
Common Stock, Value, Issued

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

CEO	Mr. Kevin R. Lind
WEBSITE	longboardpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	32

Longboard Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Longboard Pharmaceuticals, Inc.? What does LBPH stand for in stocks?

LBPH is the stock ticker symbol of Longboard Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Longboard Pharmaceuticals, Inc. (LBPH)?

As of Thu May 16 2024, market cap of Longboard Pharmaceuticals, Inc. is 797.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LBPH stock?

You can check LBPH's fair value in chart for subscribers.

What is the fair value of LBPH stock?

You can check LBPH's fair value in chart for subscribers. The fair value of Longboard Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Longboard Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LBPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Longboard Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether LBPH is over valued or under valued. Whether Longboard Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Longboard Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LBPH.